[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurocognition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurocognition":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100642879","phase-4-effect-of-supplemental-oxygen-therapy-on-neurocognitive-performance-in-healthy-highlanders-100642879",false,"NCT07651917","Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders","SPIRIT_1","Inclusion Criteria:\n\n* Signed written consent\n* Age \\>18\n* Kyrgyz ethnicity\n* Born, raised and living at approximately 2500 m\n* Native or fluent in Russian language\n\nExclusion Criteria:\n\n* Severe disease such as unstable hypertension, coronary heart disease, pulmonary diseases, others.\n* Regular use of medication that interfere with sleep or breathing such as benzodiazepines, opioids, acetazolamide\n* Heavy smoking of \\>20 cigarettes per day\n* Not able to read or adhere to the study protocol",true,"ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Exposure to high altitudes, defined as locations above 2500 m, has been shown to cause cognitive alternations due to reduced blood oxygenation (SpO2). However, it remains to be determined whether cognitive changes are present in highlanders living at moderate altitudes (2500 m) and whether cognitive alterations are reversible with supplemental oxygen therapy (SOT).",[27],"Neurocognition",[29,30,31],"Hypoxia","Altitude","Supplemental oxygen therapy","NOT_YET_RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-16","ACTUAL",{"date":38,"type":21},"2026-06-18",{"date":40,"type":21},"2026-07-31",{"name":42,"class":43},"University of Zurich","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100638789","pacu-discharge-readiness-100638789","NCT07588542","PACU Discharge Readiness","Development of Assessment Tools for Determining Outpatient Subjects' Home-Readiness After Receiving Anesthesia (Without Family or Friend to Drive Them Home)","Inclusion Criteria:\n\n* The individuals will be identified from the operating room (OR) schedule and approached in the pre-operative area (or earlier, when possible).\n* Adult patients (18 years or older) listed for surgery and a planned 23-hour admission will be eligible for enrollment in this study.\n* Subjects must be fluent in English and not have confounding sensory or neurological limitations to participation\n\nExclusion Criteria:\n\n* Members of vulnerable populations or adults unable to consent will be included in this study.\n* Subjects that do not speak English\n* Subjects with neurological limirations",{"count":52,"type":21},1000,[54],"NA","The use of custom-created apps, neuropsychological testing, and clinical assessments will be evaluated as tools for determining the appropriateness of PACU discharge to home.",[57,27,58],"Patient Discharge","Baseline","2026-05-08",{"date":61,"type":36},"2026-05-14",{"date":63,"type":21},"2026-05-01",{"date":65,"type":21},"2032-04-01",{"name":67,"class":43},"University of Illinois at Chicago",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":68},"100624428","assessment-of-informal-support-provided-by-caregivers-at-different-stages-of-alzheimers-disease-100624428","NCT07409506","Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease","ICAD","Inclusion Criteria:\n\n* Patients from Charpennes Hospital included in the MEM-AURA cohort\n* Patients aged 60 years and older at inclusion\n* Patients with dementia due to clinically probable Alzheimer's disease, regardless of stage\n* Patients with a Mini-Mental State Evaluation (MMSE) score ≤ 26 at inclusion\n* Patients accompanied by a caregiver at inclusion\n\nExclusion Criteria:\n\n* \\- Patients or caregivers who have expressed their opposition to the study\n* Patients living in institutions or nursing homes\n* Patients protected by law (under legal protection, guardianship, or conservatorship)\n\nEarly termination Criteria :\n\n\\- Patients or caregivers withdrawing their consent to participate during the study","60 Years",{"count":78,"type":21},312,"OBSERVATIONAL","In France, approximately 1,200,000 people aged 65 and over suffer from Alzheimer's disease or related disorders, of which Alzheimer's disease (AD) accounts for 70% of cases. This prevalence could double by 2050. The cognitive decline and progression to functional dependence that accompany AD are associated with a decline in quality of life, an increased risk of comorbidities, institutionalization, and mortality, as well as high care costs, placing a burden on the patient, their family and friends, and the healthcare system.\n\nInformal care, i.e., care provided by a family member or caregiver, plays an important role in the overall management of major neurocognitive disorders (NCDs) associated with AD at home. In France, the annual cost of informal care for AD was estimated in 2008 at around €14 billion per year, or approximately 50% of the total annual cost of AD. The economic valuation of informal care serves to inform public decision-makers not only about the cost of this resource, but also about its usefulness. The issue of resource allocation (particularly the daily allowance for family caregivers - AJPA in French) at the societal level and the sharing of private (role of caregivers) and public (role of the state and local authorities) responsibilities leads us to question the determinants of this usefulness, particularly the clinical determinants in AD patients at different stages of the disease.\n\nThe main hypothesis is that informal care varies according to cognitive decline and loss of autonomy, independently or in interaction with the number and type of the patient's comorbidities, their behavioral disorders, and the caregiver's burden.",[82,27,83],"Elderly (People Aged 65 or More)","Alzheimer s Disease",[85,86,87],"informal care","cost of alzheimer's disease","caregiver","RECRUITING","2026-02-12",{"date":91,"type":36},"2026-02-13",{"date":93,"type":36},"2025-09-09",{"date":95,"type":21},"2027-09-09",{"name":97,"class":43},"Hospices Civils de Lyon"]